Daix (France), Long Island City (New York, United States), July 7, 2022 – Inventiva (EuronextParisandNasdaq:IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of NASH and other diseases with significant unmet medical needs, today announced the screening in the United States of America of the first patient in its LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with NASH and T2D 1. Over 30 sites located in France, United Kingdom, Belgium, Netherlands and United States have already been qualified to participate in this clinical trial. Topline results are expected to be published in the second half of 2023.
Read more at globenewswire.comInventiva announces the screening of the first patient in LEGEND, a Phase IIa combination trial with lanifibranor and empagliflozin in patients with NASH and T2D
Globe Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
/AI%20(artificial%20intelligence)/AI%20engineer%20working%20on%20laptop%20by%20ART%20STOCK%20CREATIVE%20via%20Shutterstock.jpg)
/Semiconductor%20by%20Gorodenkoff%20via%20Shutterstock.jpg)